Study | Combi-AD [32] | EORTC-19071 [18] | Checkmate-238 [33] | |||
---|---|---|---|---|---|---|
Branch | Dab + Tram | Placebo | Ipilimumab | Placebo | Nivolumab | Ipilimumab |
Number of Patients | 438 | 432 | 475 | 476 | 453 | 453 |
Gender (Male) | 44.5 | 44.7 | 62.3 | 61.6 | 57.0 | 59.4 |
Age: Median, Range | 50 (18–89) | 51 (20–85) | 51 (20–84) | 52 (18–78) | 56 (19–83) | 54 (18–86) |
Proportion < 65 years | Not reported | 82.9 | 81.7 | 73.5 | 74.8 | |
Disease Stage | ||||||
IIIa (%) | 18.9 | 16.4 | 20.6 | 20.6 | – | – |
IIIb (%) | 38.6 | 43.3 | 38.3 | 38.2 | 36.0 | 32.7 |
IIIc (%) | 41.3 | 38.4 | 25.7 | 25.4 | 45.0 | 48.1 |
III (Not Specified, %) | 1.1 | 1.9 | ||||
IV (%) | 15.4 | 15.8 | 18.1 | 19.2 | ||
Not Reported | – | – | 1.0 | – | ||
Stage III lymph node involvement | ||||||
Microscopic (%) | 34.7 | 36.3 | 44.2 | 40.5 | 33.9 | 36.6 |
Macroscopic (%) | 36.1 | 37.3 | 55.8 | 49.5 | 59.3 | 58.5 |
Not Reported | 29.2 | 26.4 | – | – | 6.8 | 4.9 |